Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Corporate Authors: German Consortium for Familial Intestinal Cancer
- Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
- Language: English
- [Int J Cancer] 2021 Jan 01; Vol. 148 (1), pp. 106-114. <i>Date of Electronic Publication: </i>2020 Oct 13.
- MeSH Terms: Colorectal Neoplasms, Hereditary Nonpolyposis / *complications ; Early Detection of Cancer / *methods ; Gastroscopy / *statistics & numerical data ; Stomach Neoplasms / *diagnosis ; Adult ; Age Factors ; Aged ; Colorectal Neoplasms, Hereditary Nonpolyposis / genetics ; Early Detection of Cancer / standards ; Early Detection of Cancer / statistics & numerical data ; Evaluation Studies as Topic ; Gastric Mucosa / diagnostic imaging ; Gastric Mucosa / pathology ; Gastroscopy / standards ; Genetic Predisposition to Disease ; Germany / epidemiology ; Humans ; Male ; Middle Aged ; MutL Protein Homolog 1 / genetics ; MutS Homolog 2 Protein / genetics ; Mutation ; Neoplasm Staging ; Patient Compliance / statistics & numerical data ; Practice Guidelines as Topic ; Prospective Studies ; Stomach Neoplasms / epidemiology ; Stomach Neoplasms / genetics ; Stomach Neoplasms / pathology
- References: Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129:415-421. ; Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481-1487. ; Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193-2200. ; Hampel H, de la Chapelle A. How do we approach the goal of identifying everybody with Lynch syndrome? Fam Cancer. 2013;12:313-317. ; Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res. 1994;14:1635-1639. ; Lamberti C, Mangold E, Pagenstecher C, et al. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion. 2006;74:58-67. ; Win AK, Jenkins MA, Dowty JG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2017;26:404-412. ; Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214-218. ; Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. ; Capelle LG, Van Grieken NC, Lingsma HF, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in The Netherlands. Gastroenterology. 2010;138:487-492. ; Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012;30:4409-4415. ; Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141-149. ; Bericht zum Krebsgeschehen in Deutschland 2016. Zentrum für Krebsregisterdaten im Robert Koch-Institut (Hrsg). Berlin. ; Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M. Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer. 2017;117:1702-1710. ; Karimi M, von Salome J, Aravidis C, et al. A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families. Hered Cancer Clin Pract. 2018;16:16. ; Schmiegel W, Buchberger B, Follmann M, et al. S3-Leitlinie - Kolorektales Karzinom. Z Gastroenterol. 2017;55:1344-1498. ; Uitgave van de. Stichting Opsporing Erfelijke Tumoren en de Vereniging Klinische Genetica Nederland, Werkgroep Klinische Oncogenetica. Erfelijke tumoren: Richtlijnen voor diagnostiek en preventie. 2017. ISBN/EAN 978-90-806183-0-5. ; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2019 https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed August 8, 2019. ; Goecke T, Schulmann K, Engel C, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC consortium. J Clin Oncol. 2006;24:4285-4292. ; Mangold E, Pagenstecher C, Friedl W, et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer. 2005;116:692-702. ; Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:174-182. ; Saragoni L, Scarpi E, Ravaioli A, et al. Early gastric cancer: clinical behavior and treatment options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist. 2018;23:852-858. ; Sano T, Katai H, Sasako M, Maruyama K. The management of early gastric cancer. Surg Oncol. 2000;9:17-22. ; Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101-112. ; Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumors. Hoboken, NJ: Wiley-Blackwell; 2016. ; Schulmann K, Engel C, Propping P, Schmiegel W. Small bowel cancer risk in Lynch syndrome. Gut. 2008;57:1629-1630. ; Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304-2310. ; Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. Genet Med. 2020;22:15-25. ; Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444-449. ; Vasen HF, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001;19:4074-4080. ; Geary J, Sasieni P, Houlston R, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer. 2008;7:163-172. ; Kastrinos F, Stoffel EM, Balmana J, Steyerberg EW, Mercado R, Syngal S. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17:2044-2051. ; Jager AC, Bisgaard ML, Myrhoj T, Bernstein I, Rehfeld JF, Nielsen FC. Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet. 1997;61:129-138. ; Ten Broeke SW, van der Klift HM, Tops CMJ, et al. Cancer risks for PMS2-associated Lynch syndrome. J Clin Oncol. 2018;36:2961-2968. ; Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009;10:400-408. ; Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76:1-18. ; Hendriks YM, de Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. 2006;56:213-225. ; Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507-1517. ; Gupta S, Provenzale D, Regenbogen SE, et al. NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 3.2017. J Natl Compr Canc Netw. 2017;15:1465-1475. ; Provenzale D, Gupta S, Ahnen DJ, et al. Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:1010-1030. ; Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014;109:1159-1179. ; Kim J, Braun D, Ukaegbu C, et al. Clinical factors associated with gastric cancer in individuals with Lynch syndrome. Clin Gastroenterol. Hepatol. 2020;18(4):830-837.e1. http://dx.doi.org/10.1016/j.cgh.2019.07.012. ; Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2002;37:574-577. ; Soer EC, Leicher LW, Langers AM, et al. Equivalent Helicobacter pylori infection rates in Lynch syndrome mutation carriers with and without a first-degree relative with gastric cancer. Int J Colorectal Dis. 2016;31:693-697. ; Galiatsatos P, Labos C, Jeanjean M, Miller K, Foulkes WD. Low yield of gastroscopy in patients with Lynch syndrome. Turk J Gastroenterol. 2017;28:434-438. ; Moller P, Seppala TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. Gut. 2017;66:1657-1664.
- Contributed Indexing: Keywords: HNPCC; Lynch syndrome; gastric cancer; screening; surveillance
- Substance Nomenclature: 0 (MLH1 protein, human) ; EC 3.6.1.3 (MSH2 protein, human) ; EC 3.6.1.3 (MutL Protein Homolog 1) ; EC 3.6.1.3 (MutS Homolog 2 Protein)
- Entry Date(s): Date Created: 20200915 Date Completed: 20210610 Latest Revision: 20210610
- Update Code: 20240513
|